Clinical Trials Directory

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.

Stanford is now accepting new patients for this trial.

Investigator(s):

Intervention(s):

  • drug : Propofol and Fentanyl administration

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - 70 Years

Inclusion Criteria

- Inclusion criteria include patients of adult age - American Society of Anesthesiologists Class I, II, or III, and undergoing elective surgical procedures requiring general anesthesia - Body mass index greater than 35

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jerry Ingrande, M.D., M.S.
650-723-7377
Recruiting

Footer Links: